We are live on ! Find out more
NEUP icon

Neuphoria Therapeutics
NEUP

12 hedge funds and large institutions have $1.74M invested in Neuphoria Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

502% more capital inflows, than outflows

Capital inflows: $1.18M | Capital outflows: $196K

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

33% more funds holding

Funds holding: 9 → 12 (+3)

6.04% more ownership

Funds ownership: 11.07% → 17.11% (+6%)

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$1.11M
2
Two Sigma Securities
Two Sigma Securities
New York
+$23.6K
3
UBS Group
UBS Group
Switzerland
+$22.7K
4
XTX Topco
XTX Topco
Cayman Islands
+$9.9K
5
Lewis Asset Management
Lewis Asset Management
California
+$7.26K

Top Sellers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
-$195K
2
Two Sigma Investments
Two Sigma Investments
New York
-$642

NEUP Hedge Fund Activity: Q2 2024 in Review

12 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q2 2024, worth a combined $1.74M — up 43% from $1.22M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NEUP positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.11M. The largest seller was Lynx1 Capital Management, cutting an estimated $195K.

  • 12 institutional investors held Neuphoria Therapeutics (NEUP) as of Q2 2024, up from 9 in Q1 2024.
  • Funds reported $1.74M of Neuphoria Therapeutics stock for Q2 2024, up 43% quarter-over-quarter.
  • 3 funds opened new Neuphoria Therapeutics positions in Q2 2024 and 0 closed out, a net change of +3 holders.
  • The largest Neuphoria Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $1.11M added.
  • The largest Neuphoria Therapeutics seller in Q2 2024 was Lynx1 Capital Management, an estimated $195K sold.

Based on aggregated 13F filings for Q2 2024.